Shukra Pharma receives Rs 600 Cr facility from YEIDA to advance surgical robotics, cancer therapy

image credit- freepik

Shukra Pharmaceuticals has received a letter of intent from the Yamuna Expressway Industrial Development Authority (YEIDA) for 10 acres of land in the Medical Device Park, Sector 28, Greater Noida, with a planned investment of approximately Rs 600 crore.

The facility will produce advanced surgical robotics and Boron Neutron Capture Therapy (BNCT) technology, an innovative treatment for complex cancer cases. The project is expected to generate over 900 direct and approximately 2,000 indirect employment opportunities, positioning India at the forefront of health innovation.

Shukra Pharmaceuticals has also signed a Memorandum of Understanding (MoU) with Borns Medical Robotics Inc. to bring cutting-edge surgical robotics technology to India.

The partnership, formalised at an event in New Delhi, will introduce the Veer Surgical Robot; an artificial intelligence (AI)-driven surgical platform designed to enhance precision, safety, and patient outcomes while making advanced healthcare technology accessible to millions of Indians.

The partnership will establish manufacturing and distribution capabilities in India, creating a robust ecosystem for robotic surgery. The collaboration aims to train surgeons, build infrastructure, and expand access to minimally invasive surgical options across tier-2 and tier-3 cities, where advanced healthcare technology has traditionally been limited.

The first-ever human clinical trial of the Veer Surgical Robot evaluated its safety and efficacy across basic to advanced procedures, with results demonstrating excellent safety, precision, and clinical outcomes, establishing it as a reliable surgical platform. The findings from the trial have been published in leading international journals and reported to the CDSCO. The Veer Surgical Robot is expected to be deployed across leading hospitals beginning in Q2 2026, with plans to scale rapidly across the country.